Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics is well-positioned for success due to its focus on developing treatments for inherited retinal diseases and other retinal and refractive disorders, which have a sizable market globally. The company also has a strong pipeline of seven adeno-associated virus (AAV) based programs, targeting a range of genetic mutations and diseases with a particular focus on rare diseases. With its experienced management team and partnerships with foundations and a government agency, Opus is well-equipped to advance its pipeline and achieve commercial success. However, the success of its two lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, is crucial to the company's future and any failure could adversely affect its business. Opus also faces financial risks, as the majority of its earning potential comes from assets that are not yet commercial, and it will require substantial funds to finance clinical development and commercialization of its products.

Bears say

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other ophthalmic disorders. While there are encouraging results in animal models, the company faces risks in terms of intellectual property, regulatory approval, and competition, which could impact the success of its clinical trials and commercialization efforts. Additionally, there is a risk of stock price volatility in the near-term due to fluctuations in the market and the inherent risk associated with investing in biotech companies. Despite advancements and partnerships, Opus' pipeline is still in early stages and it will require further clinical data and validation before realizing its full potential in the market.

Opus Genetics (IRD) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Buy based on their latest research and market trends.

According to 11 analysts, Opus Genetics (IRD) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.